<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUPRANE- desfluraneÂ liquidÂ </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SUPRANE safely and effectively.  See full prescribing information for Suprane.<br><br>SUPRANE (desflurane, USP) liquid, for inhalation use<br>Initial U.S. Approval: 1992</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">SUPRANE is an inhalation agent indicated: </p>
<dl>
<dt>â€¢</dt>
<dd>for induction and/or maintenance of anesthesia in adults (<a href="#i4i_section_id_09158922-8be3-4de5-b0c5-b325ea292dea">1.1</a>)</dd>
<dt>â€¢</dt>
<dd>for maintenance of anesthesia in pediatric patients following induction with agents other than Suprane (desflurane, USP) and intubation. </dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>SUPRANE should be administered only by persons trained in the administration of general anesthesia. It should only be administered using a vaporizer specifically designed and designated for use with SUPRANE. (<a href="#i4i_dosage_admin_id_311c4efe-6074-4334-9120-1a8c4e069227">2</a>)</dd>
<dt>â€¢</dt>
<dd>The administration of general anesthesia must be individualized based on the patientâ€™s response, including cardiovascular and pulmonary changes. (<a href="#i4i_dosage_admin_id_311c4efe-6074-4334-9120-1a8c4e069227">2</a>)</dd>
<dt>â€¢</dt>
<dd>SUPRANE should not be used as the sole agent for anesthetic induction in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or where increases in heart rate or blood pressure are undesirable. (<a href="#i4i_section_id_8945aad2-f408-42e3-a1c0-933d12961381">2.6</a>)</dd>
<dt>â€¢</dt>
<dd>Patients with intracranial space occupying lesions (<a href="#i4i_section_id_c438a86e-9950-47cf-ab27-3aec8f934c06">2.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Liquid (volatile): 100% (<a href="#i4i_dosage_form_strength_id_69823116-6697-4922-b987-da9c4cbcc157">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Patients with known or suspected genetic susceptibility to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> (<a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">4</a>)</dd>
<dt>â€¢</dt>
<dd>Patients in whom general anesthesia is contraindicated (<a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">4</a>)</dd>
<dt>â€¢</dt>
<dd>Induction of anesthesia in pediatric patients (<a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">4</a>)</dd>
<dt>â€¢</dt>
<dd>Patients with known sensitivity to halogenated agents (<a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">4</a>, <a href="#i4i_section_id_ff33eee0-284b-410c-a4b8-2c04cf7cb75d">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>Patients with a history of moderate to severe hepatic dysfunction following anesthesia with halogenated agents and not otherwise explained. (<a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">4</a>, <a href="#i4i_section_id_ff33eee0-284b-410c-a4b8-2c04cf7cb75d">5.5</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant hyperthermia</span> may occur. (<a href="#i4i_section_id_a0647ba9-228e-446a-a892-65e5ad6188f5">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may occur. Patients with latent or overt neuromuscular disease, particularly with <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span>, appear to be most vulnerable. (<a href="#i4i_section_id_e40f232c-2d90-4c22-bd9a-9a1f3ac94743">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>SUPRANE may cause sensitivity <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> in patients sensitized by previous exposure to halogenated anesthetics. (<a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">4</a>, <a href="#i4i_section_id_ff33eee0-284b-410c-a4b8-2c04cf7cb75d">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>SUPRANE is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions. (<a href="#i4i_section_id_7ef12bff-0568-4d4e-a5f3-38ae0a27ceac">5.3</a>, <a href="#i4i_pediatric_use_id_c68b5dcf-4c47-4f76-9dff-5501bf17e4ab">8.4</a>)</dd>
<dt>â€¢</dt>
<dd>SUPRANE may cause airway narrowing and increased airway resistance in children with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Bronchial hyperreactivity</span>. (<a href="#i4i_section_id_7ef12bff-0568-4d4e-a5f3-38ae0a27ceac">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>SUPRANE can react with desiccated CO<span class="Sub">2</span> absorbents to produce <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span>. (<a href="#i4i_section_id_475fa7a7-a2f1-4c5b-aff0-3a04ac0f819f">5.4</a>)</dd>
<dt>â€¢</dt>
<dd>There are no adequate or well-controlled studies in pregnant or lactating women or during labor and delivery. SUPRANE is a uterine relaxant. (<a href="#i4i_pregnancy_id_53cb1ee6-0fac-47ed-9dd9-05cdae07d3eb">8.1</a>, <a href="#i4i_labour_delivery_id_3d4282ea-2796-4779-8a14-e79214b9128b">8.2</a>, <a href="#i4i_nursing_mothers_id_5e31c75f-fa45-4680-87d7-f8edad0f9d4b">8.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence&gt; 10%) are <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4233530" conceptname="Interrupted breathing">breath holding</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#i4i_adverse_effects_id_36f14810-a444-427f-a870-6ac0ab83976f">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-800-262-3784 or FDA at 1-800-FDA-1088 or</span><span class="Bold"><span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Concomitant use of N<span class="Sub">2</span>O, benzodiazepines and/or opioids reduces the MAC of SUPRANE. Adjust dose accordingly. (<a href="#i4i_section_id_2603910d-3eab-4426-95e1-6e86fc4ab323">7.1</a>, <a href="#i4i_section_id_42cb8460-1683-49c8-9301-607ce012a686">7.3</a>)</dd>
<dt>â€¢</dt>
<dd>SUPRANE decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly.(<a href="#i4i_section_id_b45a1d02-6b93-4185-bcc7-5f586621930b">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pediatric: SUPRANE is contraindicated as an induction agent in children and is not indicated for maintenance of anesthesia in non-intubated children due to an increased incidence of moderate to severe respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions. (<a href="#i4i_section_id_7ef12bff-0568-4d4e-a5f3-38ae0a27ceac">5.3</a>, <a href="#i4i_pediatric_use_id_c68b5dcf-4c47-4f76-9dff-5501bf17e4ab">8.4</a>)</dd>
<dt>â€¢</dt>
<dd>Geriatric: The minimum alveolar concentration (MAC) of SUPRANE decreases with increasing patient age. (<a href="#i4i_geriatric_use_id_66fe1dd7-5ceb-4634-9412-9a62760e187d">8.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Induction of Anesthesia</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Maintenance of Anesthesia</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Preanesthetic Medication</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Induction</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Maintenance of Anesthesia in Intubated Pediatric Patients</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Recovery</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Neurosurgical Use</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Observations Related to Vaporizer Use </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Respiratory Adverse Reactions in Pediatric Patients</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Interactions with Desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon Dioxide</span> Absorbents</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatobiliary Disorders</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Laboratory Findings</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Benzodiazepines and Opioids (MAC Reduction)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Neuromuscular Blocking Agents</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Concomitant use with N<span class="Sub">2</span>O</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Ambulatory Surgery</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Cardiovascular Surgery</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Geriatric Surgery</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Neurosurgery</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Pediatric Surgery</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 Safety and Handling</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_81e1c1d8-38b9-459e-a223-58868cfa0cf8"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09158922-8be3-4de5-b0c5-b325ea292dea"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Induction of Anesthesia</h2>
<p class="First">SUPRANE (desflurane, USP) is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults.</p>
<p>SUPRANE  is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c5b4d40-62f9-426a-96e0-0b5b2eb33f53"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Maintenance of Anesthesia</h2>
<p class="First">SUPRANE is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients.</p>
<p>After induction of anesthesia with agents other than SUPRANE, and tracheal intubation, SUPRANE is indicated for maintenance of anesthesia in infants and children. SUPRANE is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and secretions [see <a href="#i4i_section_id_7ef12bff-0568-4d4e-a5f3-38ae0a27ceac">Warnings and Precautions (5.3)</a> and <a href="#i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3">Clinical Studies (14.5)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_311c4efe-6074-4334-9120-1a8c4e069227"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Only persons trained in the administration of general anesthesia should administer SUPRANE. Only a vaporizer specifically designed and designated for use with desflurane should be utilized for its administration. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. </p>
<p>SUPRANE is administered by inhalation. The administration of general anesthesia must be individualized based on the patientâ€™s response. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> increase as anesthesia with SUPRANE is deepened. The minimum alveolar concentration (MAC) of SUPRANE decreases with increasing patient age. The MAC for SUPRANE is also reduced by concomitant N<span class="Sub">2</span>O administration (see <a href="#_RefID3FC0DC4A508049239AB3DD71AD2C01A5">Table 1</a>). The dose should be adjusted accordingly. The following table provides mean relative potency based upon age and effect of N<span class="Sub">2</span>O in predominately ASA physical status I or II patients.</p>
<p>Benzodiazepines and opioids decrease the MAC of SUPRANE [see <a href="#_RefID3857BF9D2A874F818EA5F795CA6150B0">Drug Interactions (7.1, Table 3)</a>]<span class="Italics">.</span> SUPRANE also decreases the doses of neuromuscular blocking agents required [see <a href="#_RefID469BF07E243B4A10A81EBA0F3EA65590">Drug Interactions (7.2, Table 4)</a>]. The dose should be adjusted accordingly.</p>
<a name="_RefID3FC0DC4A508049239AB3DD71AD2C01A5"></a><table width="100%">
<caption><span>Table 1 </span></caption>
<col width="19%">
<col width="15%">
<col width="23%">
<col width="14%">
<col width="30%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5">
<p class="First"><span class="Bold">Effect of Age on Minimum Alveolar Concentration of Desflurane  </span></p>
<p><span class="Bold">Mean Â± SD (percent atmospheres)</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">O<span class="Sub">2</span> 100%</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N<span class="Sub">2</span>O 60%/40% O<span class="Sub">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">2 weeks</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.2 Â± 0.0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">10 weeks</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.4 Â± 0.4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">9 months</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center"><p class="First"> 10.0 Â± 0.7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.5 Â± 0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">2 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.1 Â± 0.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">3 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First"> -</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.4 Â± 0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">4 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.6 Â± 0.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">7 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.1 Â± 0.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">25 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7.3 Â± 0.0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.0 Â± 0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">45 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.0 Â± 0.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8 Â± 0.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">70 years</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.2 Â± 0.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.7 Â± 0.4</p></td>
</tr>
</tbody>
</table>
<p>N = number of crossover pairs (using up-and-down method of quantal response)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c169fce2-2379-4544-9274-16c6e4af2d98"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Preanesthetic Medication</h2>
<p class="First">Issues such as whether or not to premedicate and the choice of premedication(s) must be individualized. In clinical studies, patients scheduled to be anesthetized with SUPRANE frequently received IV preanesthetic medication, such as opioid and/or benzodiazepine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c93577b-a4eb-40da-adcd-f75b4ad64643"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Induction</h2>
<p class="First">In adults, some premedicated with opioid, a frequent starting concentration was 3% SUPRANE, increased in 0.5-1.0% increments every 2 to 3 breaths. End-tidal concentrations of 4-11%, SUPRANE with and without N<span class="Sub">2</span>O, produced anesthesia within 2 to 4 minutes. When SUPRANE was tested as the primary anesthetic induction agent, the incidence of upper airway irritation (<span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, breathholding, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and secretions) was high. During induction in adults, the overall incidence of oxyhemoglobin desaturation (SpO<span class="Sub">2</span> &lt; 90%) was 6% [seeÂ <a href="#i4i_section_id_0ae926be-d291-4dea-9762-6e300c3ccd88">Adverse Reactions (6.1)</a>]<span class="Italics">.</span></p>
<p>After induction in adults with an intravenous drug such as thiopental or propofol, SUPRANE can be started at approximately 0.5-1 MAC, whether the carrier gas is O<span class="Sub">2</span> or N<span class="Sub">2</span>O/O<span class="Sub">2</span>.</p>
<p>Inspired concentrations of SUPRANE greater than 12% have been safely administered to patients, particularly during induction of anesthesia. Such concentrations will proportionately dilute the concentration of oxygen; therefore, maintenance of an adequate concentration of oxygen may require a reduction of nitrous oxide or air if these gases are used concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_906c3d41-1074-403d-a863-e3a42f1fd1de"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Maintenance</h2>
<p class="First">Surgical levels of anesthesia in adults may be maintained with concentrations of 2.5-8.5% SUPRANE with or without the concomitant use of nitrous oxide. In children, surgical levels of anesthesia may be maintained with concentrations of 5.2-10% SUPRANE with or without the concomitant use of nitrous oxide. </p>
<p>During the maintenance of anesthesia with inflow rates of 2 L/min or more, the alveolar concentration of SUPRANE will usually be within 10% of the inspired concentration [F<span class="Sub">A</span>/F<span class="Sub">I</span>, see <a href="#_RefIDEAB9634F09104C62A1188E9AED7571F7">Figure 2 in Clinical Pharmacology (12.3)</a>].</p>
<p>During the maintenance of anesthesia, increasing concentrations of SUPRANE produce dose-dependent decreases in blood pressure. Excessive decreases in blood pressure may be due to depth of anesthesia and in such instances may be corrected by decreasing the inspired concentration of SUPRANE.</p>
<p>Concentrations of SUPRANE exceeding 1 MAC may increase heart rate. Thus with this drug, an increased heart rate may not serve reliably as a sign of inadequate anesthesia.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94fce863-5c36-41c5-9f37-a13ac5168965"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Maintenance of Anesthesia in Intubated Pediatric Patients</h2>
<p class="First">SUPRANE is indicated for maintenance of anesthesia in infants and children after induction of anesthesia with agents other than SUPRANE, and tracheal intubation.</p>
<p>SUPRANE, with or without N<span class="Sub">2</span>O, and halothane, with or without N<span class="Sub">2</span>O were studied in three clinical trials of pediatric patients aged 2 weeks to 12 years (median 2 years) and ASA physical status I or II. The concentration of SUPRANE required for maintenance of general anesthesia is age-dependent [see <a href="#i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3">Clinical Studies (14.5)</a>].</p>
<p>Changes in blood pressure during maintenance of and recovery from anesthesia with SUPRANE /N<span class="Sub">2</span>O/O<span class="Sub">2</span> are similar to those observed with halothane/N<span class="Sub">2</span>O/O<span class="Sub">2</span>. Heart rate during maintenance of anesthesia is approximately 10 beats per minute faster with SUPRANE than with halothane. Patients were judged fit for discharge from post-anesthesia care units within one hour with both SUPRANE and halothane. There were no differences in the incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> between patients receiving SUPRANE or halothane.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8befba79-7fdf-4f8f-84c2-b3eddfd0937b"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Recovery</h2>
<p class="First">The recovery from general anesthesia should be assessed carefully before patients are discharged from the post anesthesia care unit (PACU).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8945aad2-f408-42e3-a1c0-933d12961381"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, maintenance of normal hemodynamics is important to prevent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. A rapid increase in desflurane concentration is associated with marked increase in pulse rate, mean arterial pressure and levels of epinephrine and norepinephrine. SUPRANE should not be used as the sole agent for anesthetic induction in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or patients where increases in heart rate or blood pressure are undesirable. It should be used with other medications, preferably intravenous opioids and hypnotics [see <a href="#i4i_section_id_f84d835a-babd-42d9-9e2c-cfa2c4ce0b48">Clinical Studies (14.2)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c438a86e-9950-47cf-ab27-3aec8f934c06"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Neurosurgical Use</h2>
<p class="First">SUPRANE may produce a dose-dependent increase in cerebrospinal fluid pressure (CSFP) when administered to patients with intracranial space occupying lesions. SUPRANE should be administered at 0.8 MAC or less, and in conjunction with a barbiturate induction and <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> (hypocapnia) until cerebral decompression in patients with known or suspected increases in CSFP. Appropriate attention must be paid to maintain cerebral perfusion pressure [see <a href="#i4i_section_id_a6335d1c-45fc-49f8-805f-83432d845bfb">Clinical Studies (14.4)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3de58a01-95f6-4f07-a516-041d897bed54"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Observations Related to Vaporizer Use </h2>
<p class="First">Yellow discoloration of SUPRANE sometimes accompanied by particulates, has been observed through the vaporizer sight glass or after draining the vaporizer. The presence of discoloration or particulates in these situations, does not alter the quality or efficacy of SUPRANE. If observed, refer to the respective vaporizer Instructions For Use (IFU) for recommended actions or contact Baxter Product Surveillance.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_69823116-6697-4922-b987-da9c4cbcc157"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Colorless, non-flammable, volatile liquid (below 22.8Â°C) for inhalation, 100% desflurane.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">The use of SUPRANE is contraindicated in the following conditions:</p>
<dl>
<dt>â€¢</dt>
<dd>Known or suspected genetic susceptibility to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.</dd>
<dt>â€¢</dt>
<dd>Patients in whom general anesthesia is contraindicated.</dd>
<dt>â€¢</dt>
<dd>Induction of anesthesia in pediatric patients.</dd>
<dt>â€¢</dt>
<dd>Patients with known sensitivity to SUPRANE or to other halogenated agents [see <a href="#i4i_section_id_ff33eee0-284b-410c-a4b8-2c04cf7cb75d">Warnings and Precautions (5.5)</a>].</dd>
<dt>â€¢</dt>
<dd>Patients with a history of moderate to severe hepatic dysfunction following anesthesia with SUPRANE or other halogenated agents and not otherwise explained [see <a href="#i4i_section_id_ff33eee0-284b-410c-a4b8-2c04cf7cb75d">Warnings and Precautions (5.5)</a>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_8b2d5ac2-d9df-45ca-a9ca-0a0e8b2cf7b0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0647ba9-228e-446a-a892-65e5ad6188f5"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span></h2>
<p class="First">In susceptible individuals, potent inhalation anesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. In genetically susceptible pigs, desflurane induced <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. The clinical syndrome is signaled by <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and may include <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and/or unstable blood pressure. Some of these nonspecific signs may also appear during <span class="product-label-link" type="condition" conceptid="4086497" conceptname="Light anesthesia">light anesthesia</span>: acute <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>.</p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> includes discontinuation of triggering agents, administration of intravenous dantrolene sodium, and application of supportive therapy. (Consult prescribing information for dantrolene sodium intravenous for additional information on patient management.) <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> may appear later, and urine flow should be monitored and sustained if possible.</p>
<p>Fatal outcome of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> has been reported with desflurane.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e40f232c-2d90-4c22-bd9a-9a1f3ac94743"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span>, appear to be most vulnerable.  Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatinine kinase levels and, in some cases, changes in urine consistent with <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>.  Despite the similarity in presentation to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, none of these patients exhibited signs or symptoms of <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> or hypermetabolic state. Early and aggressive intervention to treat the <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and resistant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> is recommended, as is subsequent evaluation for latent neuromuscular disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ef12bff-0568-4d4e-a5f3-38ae0a27ceac"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Respiratory Adverse Reactions in Pediatric Patients</h2>
<p class="First">SUPRANE is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions [see <a href="#i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3">Clinical Studies (14.5)</a>]. </p>
<p>Children, particularly if 6 years old or younger, who are under an anesthetic maintenance of SUPRANE delivered via laryngeal mask airway (LMAâ„¢ mask) are at increased risk for adverse respiratory reactions, e.g., <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, especially with removal of the laryngeal mask airway under deep anesthesia [see <a href="#i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3">Clinical Studies (14.5)</a>]. Therefore, closely monitor these patients for signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and treat accordingly. </p>
<p>When SUPRANE is used for maintenance of anesthesia in children with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of recent upper airway <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, there is an increased risk for airway narrowing and increases in airway resistance.  Therefore, closely monitor these patients for signs and symptoms associated with airway narrowing and treat accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_475fa7a7-a2f1-4c5b-aff0-3a04ac0f819f"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Interactions with Desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon Dioxide</span> Absorbents</h2>
<p class="First">Desflurane like some other inhalation anesthetics, can react with desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> (CO<span class="Sub">2</span>) absorbents to produce <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span> that may result in elevated levels of <span class="product-label-link" type="condition" conceptid="4269049" conceptname="Carboxyhemoglobin">carboxyhemoglobin</span> in some patients. Case reports suggest that barium hydroxide lime and soda lime become desiccated when fresh gases are passed through the CO<span class="Sub">2</span> canister at high flow rates over many hours or days. When a clinician suspects that CO<span class="Sub">2</span> absorbent may be desiccated, it should be replaced before the administration of SUPRANE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff33eee0-284b-410c-a4b8-2c04cf7cb75d"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatobiliary Disorders</h2>
<p class="First">With the use of halogenated anesthetics, disruption of hepatic function, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">icterus</span> and fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> have been reported; such reactions appear to indicate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. As with other halogenated anesthetic agents, SUPRANE may cause sensitivity <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> in patients who have been sensitized by previous exposure to halogenated anesthetics [see <a href="#i4i_contraindications_id_1b01de46-335b-43da-b623-bf3550f44059">Contraindications (4)</a>]. Cirrhosis, <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span> or other pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> may be a reason to select an anesthetic other than a halogenated anesthetic. As with all halogenated anesthetics, repeated anesthesia within a short period of time should be approached with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5fe38f98-e8d6-4457-ab2b-c1c101bdd03d"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Laboratory Findings</h2>
<p class="First">Transient elevations in glucose and white blood cell count may occur as with use of other anesthetic agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_36f14810-a444-427f-a870-6ac0ab83976f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ae926be-d291-4dea-9762-6e300c3ccd88"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Adverse event information is derived from controlled clinical trials, the majority of which were conducted in the United States. The studies were conducted using a variety of premedications, other anesthetics, and surgical procedures of varying length. Most adverse events reported were mild and transient, and may reflect the surgical procedures, patient characteristics (including disease) and/or medications administered.</p>
<p>Of the 2,143 patients exposed to SUPRANE in clinical trials, 370 adults and 152 children were induced with desflurane alone and 987 patients were maintained principally with desflurane. The frequencies given reflect the percent of patients with the event. Each patient was counted once for each type of adverse event. They are presented in alphabetical order according to body system.</p>
<a name="_RefID12E8EB0A39BD41E1BC16AA0177984D5A"></a><table width="100%">
<caption><span>Table 2</span></caption>
<col width="37%">
<col width="63%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Incidence of events 3% - 10%</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Frequency of Events Occurring in Greater Than 1% of Clinical Trial Patients </span><br><span class="Bold">(in Reports Deemed â€œProbably Causally Relatedâ€?)</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Induction (use as a mask inhalation agent)</span></p></td></tr>
<tr>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Adult Patients (N=370):</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span> 34%, breathholding 30%, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> 15%, increased secretions<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span><a href="#footnote-1" class="Sup">*</a>, oxyhemoglobin desaturation (SpO<span class="Sub">2</span> &lt; 90%)<a href="#footnote-1" class="Sup">*</a>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span><a href="#footnote-1" class="Sup">*</a>.</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First"><span class="Bold">Maintenance or Recovery</span></p>
<p><span class="Bold"> Adult and Intubated Pediatric Patients (N=687):</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Body as a Whole</p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Cardiovascular</p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4217221" conceptname="Nodal rhythm disorder">nodal arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Digestive</p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> 27%, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> 16%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Nervous system</p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Increased salivation</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Respiratory  </p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span><a href="#footnote-1" class="Sup">*</a>, breathholding, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span><a href="#footnote-1" class="Sup">*</a>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span><a href="#footnote-1" class="Sup">*</a>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Special Senses</p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>  (<span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>)</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col width="31%">
<col width="69%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center" colspan="2">
<p class="First"><span class="Bold">Frequency of Events Occurring in Less Than 1% of Patients</span><br><span class="Bold">(in Reports Deemed â€œProbably Causally Relatedâ€?)</span></p>
<p><span class="Bold">Reported in 3 or more patients, regardless of severity</span></p>
</td></tr>
<tr><td align="center" colspan="2"><p class="First">Adverse reactions reported only from postmarketing experience or in the literature, not seen in clinical trials, are considered rare and are italicized.</p></td></tr>
<tr>
<td><p class="First"><span class="Bold">Cardiovascular</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">bigeminy</span>, abnormal electrocardiogram, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, vasodilation</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Digestive</span></p></td>
<td><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Nervous System</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span></p></td>
</tr>
<tr><td align="center" colspan="2">
<p class="First"><span class="Bold">Frequency of Events Occurring in Less Than 1% of Clinical Trial Patients </span><br><span class="Bold">(in Reports Deemed â€œCausal Relationship Unknownâ€?)</span></p>
<p><span class="Bold">Reported in 3 or more patients, regardless of severity </span></p>
</td></tr>
<tr>
<td><p class="First"><span class="Bold">Body as a Whole</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Cardiovascular</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Metabolic and Nutrition</span></p></td>
<td><p class="First">Increased creatinine phosphokinase</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Musculoskeletal System</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
</tr>
<tr class="Botrule Last">
<td><p class="First"><span class="Bold">Skin and Appendages</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2beab76c-e48a-4974-8d49-bc5413a3e873"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First"><span class="Italics">The following adverse reactions have been identified during post-approval use of SUPRANE. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</span></p>
<p><span class="Italics">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">Ocular icterus</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de pointes</span>, ventricular failure, ventricular <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">Malignant hypertension</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Pancreatitis acute</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">cytolytic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorder:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></p>
<p><span class="Italics">Musculoskeletal, Connective Tissue and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Hyperthermia malignant</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Italics">Investigations:</span> Electrocardiogram ST-T change, electrocardiogram T-wave inversion, tranaminases increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, blood bilirubin increased, coagulation test abnormal, <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> increased</p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications*:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="434231" conceptname="Burn confined to eye and adnexa">eye burns</span>, <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">blindness transient</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, accidental exposure, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span>, <span class="product-label-link" type="condition" conceptid="4168611" conceptname="Effect of drug maladministration">drug administration error</span></p>
<p>*All of reactions categorized within this SOC were accidental exposures to non-patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a867090a-7e64-414b-980f-40c24a68196f"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials. The effect of SUPRANE on the disposition of other drugs has not been determined. Similar to isoflurane, SUPRANE does not predispose to premature <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> in the presence of exogenously infused epinephrine in swine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2603910d-3eab-4426-95e1-6e86fc4ab323"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Benzodiazepines and Opioids (MAC Reduction)</h2>
<p class="First">Benzodiazepines and opioids decrease the amount of desflurane (MAC) needed to produce anesthesia. This effect is shown in Table 3 for intravenous midazolam (25-50 Âµg/kg) and intravenous fentanyl (3-6 Âµg/kg) in patients of two different age groups.</p>
<a name="_RefID3857BF9D2A874F818EA5F795CA6150B0"></a><table width="100%">
<caption><span>Table 3 </span></caption>
<col width="35%">
<col width="23%">
<col width="28%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">
<p class="First"><span class="Bold">SUPRANE (desflurane, USP) MAC with Fentanyl or Midazolam </span></p>
<p><span class="Bold">Mean Â± SD (percent reduction)</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Dose</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">18-30 years</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">31-65 years</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No fentanyl</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.4 Â± 0.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.3 Â± 0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">3 Âµg/kg fentanyl</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.5 Â± 1.9 (46%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.1 Â± 0.6 (51%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">6 Âµg/kg fentanyl</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.0 Â± 1.2 (53%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.3 Â± 1.0 (64%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No midazolam</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.9 Â± 0.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.9 Â± 0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">25 Âµg/kg midazolam</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.9 Â± 0.9 (16%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">50 Âµg/kg midazolam</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.9 Â± 0.5 (17%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b45a1d02-6b93-4185-bcc7-5f586621930b"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Neuromuscular Blocking Agents</h2>
<p class="First">Anesthetic concentrations of desflurane at equilibrium (administered for 15 or more minutes before testing) reduced the ED<span class="Sub">95</span> of succinylcholine by approximately 30% and that of atracurium and pancuronium by approximately 50% compared to N<span class="Sub">2</span>O/opioid anesthesia (see <a href="#_RefID469BF07E243B4A10A81EBA0F3EA65590">Table 4</a>). The effect of desflurane on duration of nondepolarizing <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> has not been studied.</p>
<a name="_RefID469BF07E243B4A10A81EBA0F3EA65590"></a><table width="100%">
<caption><span>Table 4  </span></caption>
<col width="22%">
<col width="22%">
<col width="17%">
<col width="20%">
<col width="19%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Dosage of Muscle Relaxant Causing 95% <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></span><br><span class="Bold">in <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">Neuromuscular Blockade</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"><span class="Bold">Desflurane Concentration</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="4"><p class="First"><span class="Bold">Mean ED<span class="Sub">95</span> (Âµg/kg)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pancuronium</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Atracurium</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Succinylcholine</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Vecuronium</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">0.65 MAC  60% N<span class="Sub">2</span>O/O<span class="Sub">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule" align="center"><p class="First">133</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1.25 MAC  60% N<span class="Sub">2</span>O/O<span class="Sub">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule" align="center"><p class="First">119</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">1.25 MAC  O<span class="Sub">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule" align="center"><p class="First">120</p></td>
<td class="Botrule Lrule" align="center"><p class="First">360</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
</tr>
</tbody>
</table>
<p>Dosage reduction of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span>, because potentiation of neuromuscular blocking agents requires equilibration of muscle with the delivered partial pressure of SUPRANE.</p>
<p>Among nondepolarizing drugs, pancuronium, atracurium, and vecuronium interactions have been studied. In the absence of specific guidelines:</p>
<dl>
<dt>1.</dt>
<dd>For endotracheal intubation, do not reduce the dose of nondepolarizing muscle relaxants or succinylcholine.</dd>
<dt>2.</dt>
<dd>During maintenance of anesthesia, the dose of nondepolarizing muscle relaxants is likely to be reduced compared to that during N<span class="Sub">2</span>O/opioid anesthesia. Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42cb8460-1683-49c8-9301-607ce012a686"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Concomitant use with N<span class="Sub">2</span>O</h2>
<p class="First">Concomitant administration of N<span class="Sub">2</span>O reduces the MAC of SUPRANE [see <a href="#_RefID3FC0DC4A508049239AB3DD71AD2C01A5">Dosage and Administration (2), Table 1</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_6fc69928-e150-4e21-a7a5-4ae29dc49a8b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_53cb1ee6-0fac-47ed-9dd9-05cdae07d3eb"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies areÂ not always predictive of humanÂ response, this drug should be usedÂ during pregnancy only if clearly needed. Reproduction studies have beenÂ performed in rats atÂ doses up to at 1 MAC hour for a minimum of 21 daysÂ and have revealed no evidence ofÂ impaired fertility or harm to the fetus due to SUPRANE.Â </p>
<p>No teratogenic effect was observed at approximately 10 and 13 cumulative MAC-Hour exposures at 1Â MAC-Hour per day during organogenesis in rats or rabbits. At higher doses increased incidences of post-implantation loss and maternal toxicity were observed. However, at 10 MAC-Hours cumulative exposure in rats, about 6% decrease in the weight of male pups was observed at preterm caesarean delivery. </p>
<p>Rats exposed to SUPRANE at 1 MAC-Hour per day from gestation day 15 to lactation day 21, did not show signs of dystocia. Body weights of pups delivered by these dams at birth and during lactation were comparable to that of control pups. No treatment related behavioral changes were reported in these pups during lactation.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_3d4282ea-2796-4779-8a14-e79214b9128b"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The safety of SUPRANE during labor or delivery has not been demonstrated. SUPRANE is a uterine-relaxant.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_5e31c75f-fa45-4680-87d7-f8edad0f9d4b"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not knownÂ whether this drug is excreted in humanÂ milk. Because many drugs are excretedÂ in human milk, caution should beÂ exercised when SUPRANE isÂ administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_c68b5dcf-4c47-4f76-9dff-5501bf17e4ab"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41258406-f1a1-4cf1-ad64-45a28e0be992"></a><a name="section-8.4.1"></a><p></p>
<h3>Respiratory Adverse Reactions in Pediatric Patients</h3>
<p class="First">SUPRANE is indicated for maintenance of anesthesia in infants and children after induction of anesthesia with agents other than SUPRANE , and tracheal intubation.</p>
<p>Is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (26%), <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> (13%) and secretions (12%) [see <a href="#i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3">Clinical Studies (14.5)</a>]. </p>
<p>Children, particularly if 6 years old or younger, who are under an anesthetic maintenance of SUPRANE delivered via laryngeal mask airway (LMAâ„¢ mask) are at increased risk for adverse respiratory reactions, e.g., <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, especially with removal of the laryngeal mask airway under deep anesthesia [see <a href="#i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3">Clinical Studies (14.5)</a>]. Therefore, closely monitor these patients for signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and treat accordingly.</p>
<p>When SUPRANE is used for maintenance of anesthesia in children with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of recent upper airway <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, there is an increased risk for airway narrowing and increases in airway resistance.  Therefore, closely monitor these patients for signs and symptoms associated with airway narrowing and treat accordingly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_66fe1dd7-5ceb-4634-9412-9a62760e187d"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The minimum alveolar concentration (MAC) of SUPRANE decreases with increasing patient age. The dose should be adjusted accordingly. The average MAC for SUPRANE in a 70 year old patient is two-thirds the MAC for a 20 year old patient [see  <a href="#_RefID3FC0DC4A508049239AB3DD71AD2C01A5">Dosage and Administration (2) Table 1</a> and <a href="#i4i_section_id_eeb61e04-a960-4e52-bf8f-89268d30b3d6">Clinical Studies (14.3)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_36e3792d-2dc5-4354-a9a9-8ef7e62332bb"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Concentrations of 1-4% SUPRANE in nitrous oxide/oxygen have been used in patients with chronic renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and during renal transplantation surgery.</p>
<p>Because of minimal metabolism, a need for dose adjustment in patients with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not to be expected.</p>
<p>Nine patients receiving desflurane (N=9) were compared to 9 patients receiving isoflurane, all with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> (serum creatinine 1.5-6.9 mg/dL). No differences in hematological or biochemical tests, including renal function evaluation, were seen between the two groups. Similarly, no differences were found in a comparison of patients receiving either desflurane (N=28) or isoflurane (N=30) undergoing renal transplant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_985d21a2-f5c8-477d-a129-063bb4fde50f"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Eight patients receiving SUPRANE were compared to six patients receiving isoflurane, all with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> (<span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4340383" conceptname="Alcoholic hepatitis">alcoholic hepatitis</span>, or cirrhosis). No differences in hematological or biochemical tests, including hepatic enzymes and hepatic function evaluation, were seen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_8655c2da-7c96-430a-9c86-e0e3cbd58327"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The symptoms of overdosage of SUPRANE can present as a deepening of anesthesia, cardiac and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in spontaneously breathing patients, and cardiac <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in ventilated patients in whom <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> may occur only at a late stage. In the event of overdosage, or suspected overdosage, take the following actions: discontinue administration of SUPRANE, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_2c55c101-1d00-419c-b6e7-a5aa5e8d2fda"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">SUPRANE (desflurane, USP), a nonflammable liquid administered via vaporizer, is a general inhalation anesthetic. It is (Â±)1,2,2,2-tetrafluoroethyl difluoromethyl ether:</p>
<div class="Figure">
<a name="id970"></a><img alt="Suprane Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5&amp;name=image-01.jpg">
</div>
<p>Some physical constants are:</p>
<table width="100%">
<col width="49%">
<col width="51%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First">Molecular weight</p></td>
<td><p class="First">168.04</p></td>
</tr>
<tr>
<td><p class="First">Specific gravity (at 20Â°C/4Â°C)</p></td>
<td><p class="First">1.465</p></td>
</tr>
<tr>
<td><p class="First">Vapor pressure in mm Hg</p></td>
<td><p class="First">669 mm Hg @ 20Â°C</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">731 mm Hg @ 22Â°C</p></td>
</tr>
<tr>
<td></td>
<td>
<p class="First">757 mm Hg @ 22.8Â°C</p>
<p>(boiling point;1atm)</p>
</td>
</tr>
<tr>
<td></td>
<td><p class="First">764 mm Hg @ 23Â°C</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">798 mm Hg @ 24Â°C</p></td>
</tr>
<tr class="Botrule Last">
<td></td>
<td><p class="First">869 mm Hg @ 26Â°C</p></td>
</tr>
</tbody>
</table>
<p>Partition coefficients at 37Â°C:</p>
<table width="100%">
<col width="35%">
<col width="21%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First">Blood/Gas</p></td>
<td><p class="First">0.424</p></td>
</tr>
<tr>
<td><p class="First">Olive Oil/Gas</p></td>
<td><p class="First">18.7</p></td>
</tr>
<tr class="Botrule Last">
<td><p class="First">Brain/Gas</p></td>
<td><p class="First">  0.54</p></td>
</tr>
</tbody>
</table>
<p>Mean Component/Gas Partition Coefficients:</p>
<table width="100%">
<col width="62%">
<col width="21%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First">Polypropylene (Y piece)</p></td>
<td><p class="First">  6.7</p></td>
</tr>
<tr>
<td><p class="First">Polyethylene (circuit tube)</p></td>
<td><p class="First">16.2</p></td>
</tr>
<tr>
<td><p class="First">Latex rubber (bag)</p></td>
<td><p class="First">19.3</p></td>
</tr>
<tr>
<td><p class="First">Latex rubber (bellows)</p></td>
<td><p class="First">10.4</p></td>
</tr>
<tr class="Botrule Last">
<td><p class="First">Polyvinylchloride (endotracheal tube)</p></td>
<td><p class="First">34.7</p></td>
</tr>
</tbody>
</table>
<p>SUPRANE (desflurane, USP) is nonflammable as defined by the requirements of International Electrotechnical Commission 601-2-13.</p>
<p>SUPRANE (desflurane, USP) is a colorless, volatile liquid below 22.8Â°C. Data indicate that SUPRANE (desflurane, USP) is stable when stored under normal room lighting conditions according to instructions.</p>
<p>SUPRANE (desflurane, USP) is chemically stable. The only known degradation reaction is through prolonged direct contact with soda lime producing low levels of fluoroform (CHF<span class="Sub">3</span>). The amount of CHF<span class="Sub">3</span> obtained is similar to that produced with MAC-equivalent doses of isoflurane. No discernible degradation occurs in the presence of strong acids.</p>
<p>SUPRANE (desflurane, USP) does not corrode stainless steel, brass, aluminum, anodized aluminum, nickel plated brass, copper, or beryllium. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_826f57bc-9f39-4cbc-ada1-7d7cb60d9fe6"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_0d70ec85-d3aa-4ce3-af82-61f96d839824"></a><a name="section-11.1"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Changes in the clinical effects of SUPRANE rapidly follow changes in the inspired concentration. The duration of anesthesia and selected recovery measures for SUPRANE are given in the following tables:</p>
<p>In 178 female outpatients undergoing laparoscopy, premedicated with fentanyl (1.5-2.0Â Âµg/kg), anesthesia was initiated with propofol 2.5 mg/kg, desflurane/N<span class="Sub">2</span>O 60% in O<span class="Sub">2</span> or desflurane/O<span class="Sub">2</span> alone. Anesthesia was maintained with either propofol 1.5-9.0 mg/kg/hr, desflurane 2.6-8.4% in N<span class="Sub">2</span>O 60% in O<span class="Sub">2</span>, or desflurane 3.1-8.9% in O<span class="Sub">2</span>.</p>
<table width="100%">
<col width="25%">
<col width="17%">
<col width="20%">
<col width="20%">
<col width="18%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Differences were statistically significant (p &lt; 0.05) by Dunnettâ€™s procedure comparing all treatments to the propofol-propofol/N<span class="Sub">2</span>O (induction and maintenance) group. Results for comparisons greater than one hour after anesthesia show no differences between groups and considerable variability within groups.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Emergence and Recovery After Outpatient Laparoscopy</span><br><span class="Bold">178 Females, Ages 20-47</span><br><span class="Bold">Times in Minutes: Mean Â± SD (Range)</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Induction:</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Propofol</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Propofol</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Desflurane/O<span class="Sub">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Maintenance:</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Propofol/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Desflurane/O<span class="Sub">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Number of Pts:</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N = 48</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N = 44</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N = 43</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N = 43</span></p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Median age</span></p></td>
<td class="Lrule" align="center"><p class="First">30</p></td>
<td class="Lrule" align="center"><p class="First">26</p></td>
<td class="Lrule" align="center"><p class="First">29</p></td>
<td class="Lrule Rrule" align="center"><p class="First">30</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(20 - 43)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(21 - 47)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(21 - 42)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(20 - 40)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Anesthetic time</span></p></td>
<td class="Lrule" align="center"><p class="First">49 Â± 53</p></td>
<td class="Lrule" align="center"><p class="First">45 Â± 35</p></td>
<td class="Lrule" align="center"><p class="First">44 Â± 29</p></td>
<td class="Lrule Rrule" align="center"><p class="First">41 Â± 26</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(8 - 336)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(11 - 178)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(14 - 149)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(19 - 126)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to open eyes</span></p></td>
<td class="Lrule" align="center"><p class="First">7 Â± 3</p></td>
<td class="Lrule" align="center"><p class="First">5 Â± 2<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">5 Â± 2<a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Lrule Rrule" align="center"><p class="First">4 Â± 2<a href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(2 - 19)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(2 - 10)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(2 - 12)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(1 - 11)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to state name</span></p></td>
<td class="Lrule" align="center"><p class="First">9 Â± 4</p></td>
<td class="Lrule" align="center"><p class="First">8 Â± 3</p></td>
<td class="Lrule" align="center"><p class="First">7 Â± 3<a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Lrule Rrule" align="center"><p class="First">7 Â± 3<a href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(4 - 22)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(3 - 18)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(3 - 16)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(2 - 15)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to stand</span></p></td>
<td class="Lrule" align="center"><p class="First">80 Â± 34</p></td>
<td class="Lrule" align="center"><p class="First">86 Â± 55</p></td>
<td class="Lrule" align="center"><p class="First">81 Â± 38</p></td>
<td class="Lrule Rrule" align="center"><p class="First">77 Â± 38</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(40 - 200)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(30 - 320)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(35 - 190)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(35 - 200)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to walk</span></p></td>
<td class="Lrule" align="center"><p class="First">110 Â± 6</p></td>
<td class="Lrule" align="center"><p class="First">122 Â± 85</p></td>
<td class="Lrule" align="center"><p class="First">108 Â± 59</p></td>
<td class="Lrule Rrule" align="center"><p class="First">108 Â± 66</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(47 - 285)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(37 â€“ 375)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(48 - 220)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(49 - 250)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to fit for</span></p></td>
<td class="Lrule" align="center"><p class="First">152 Â± 75</p></td>
<td class="Lrule" align="center"><p class="First">157 Â± 80</p></td>
<td class="Lrule" align="center"><p class="First">150 Â± 66</p></td>
<td class="Lrule Rrule" align="center"><p class="First">155 Â± 73</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">discharge</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">(66 - 375)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(73 - 385)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(68 - 310)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(69 - 325)</p></td>
</tr>
</tbody>
</table>
<p>In 88 unpremedicated outpatients, anesthesia was initiated with thiopental 3-9 mg/kg or desflurane in O<span class="Sub">2</span>. Anesthesia was maintained with isoflurane 0.7-1.4% in N<span class="Sub">2</span>O 60%, desflurane 1.8-7.7% in N<span class="Sub">2</span>O 60%, or desflurane 4.4-11.9% in O<span class="Sub">2</span>.</p>
<table width="100%">
<col width="24%">
<col width="18%">
<col width="20%">
<col width="20%">
<col width="18%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Differences were statistically significant (p &lt; 0.05) by Dunnettâ€™s procedure comparing all treatments to the thiopental-isoflurane/N<span class="Sub">2</span>O (induction and maintenance) group. Results for comparisons greater than one hour after anesthesia show no differences between groups and considerable variability within groups.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Emergence and Recovery Times in Outpatient Surgery</span><br><span class="Bold">46 Males, 42 Females, Ages 19-70</span><br><span class="Bold">Times in Minutes: Mean Â± SD (Range)</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Induction: </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Thiopental</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Thiopental</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Thiopental</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Desflurane/O<span class="Sub">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Maintenance:</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Isoflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/O<span class="Sub">2</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Desflurane/O<span class="Sub">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Number of Pts:</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N = 23</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N = 21</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N = 23</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N = 21</span></p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Median age</span></p></td>
<td class="Lrule" align="center"><p class="First">43</p></td>
<td class="Lrule" align="center"><p class="First">40</p></td>
<td class="Lrule" align="center"><p class="First">43</p></td>
<td class="Lrule Rrule" align="center"><p class="First">41</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(20 - 70)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(22 - 67)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(19 - 70)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(21-64)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Anesthetic time</span></p></td>
<td class="Lrule" align="center"><p class="First">49 Â± 23</p></td>
<td class="Lrule" align="center"><p class="First">50 Â± 19</p></td>
<td class="Lrule" align="center"><p class="First">50 Â± 27</p></td>
<td class="Lrule Rrule" align="center"><p class="First">51 Â± 23</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(11 - 94)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(16 - 80)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(16 - 113)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(19 - 117)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to open eyes</span></p></td>
<td class="Lrule" align="center"><p class="First">13 Â± 7</p></td>
<td class="Lrule" align="center"><p class="First">9 Â± 3<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">12 Â± 8</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8 Â± 2<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(5 - 33)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(4 - 16)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(4 - 39)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(4 - 13)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to state name</span></p></td>
<td class="Lrule" align="center"><p class="First">17 Â± 10</p></td>
<td class="Lrule" align="center"><p class="First">11 Â± 4<a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">15 Â± 10</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9 Â± 3<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(6 - 44)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(6 - 19)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(6 - 46)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(5 - 14)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to walk</span></p></td>
<td class="Lrule" align="center"><p class="First">195 Â± 67</p></td>
<td class="Lrule" align="center"><p class="First">176 Â± 60</p></td>
<td class="Lrule" align="center"><p class="First">168 Â± 34</p></td>
<td class="Lrule Rrule" align="center"><p class="First">181 Â± 42</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(124 - 365)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(101 - 315)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(119 - 258)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(92 - 252)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Time to fit for</span></p></td>
<td class="Lrule" align="center"><p class="First">205 Â± 53</p></td>
<td class="Lrule" align="center"><p class="First">202 Â± 41</p></td>
<td class="Lrule" align="center"><p class="First">197 Â± 35</p></td>
<td class="Lrule Rrule" align="center"><p class="First">194 Â± 37</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">discharge</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">(153 - 365)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(144 - 315)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(155 - 280)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(134 - 288)</p></td>
</tr>
</tbody>
</table>
<p>Recovery from anesthesia was assessed at 30, 60, and 90 minutes following 0.5 MAC desflurane (3%) or isoflurane (0.6%) in N<span class="Sub">2</span>O 60% using subjective and objective tests. At 30 minutes after anesthesia, only 43% of patients in the isoflurane group were able to perform the psychometric tests compared to 76% in the SUPRANE group (p &lt; 0.05).</p>
<table width="100%">
<col width="20%">
<col width="22%">
<col width="21%">
<col width="19%">
<col width="17%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Visual analog scale (values from 0-100; 100 = baseline)</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">â€ </a></dt>
<dd>Differences were statistically significant (p &lt; 0.05) using a two-sample t-test</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€¡</a></dt>
<dd>DSST = Digit Symbol Substitution Test</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Â§</a></dt>
<dd>Trieger Test = Dot Connecting Test</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Recovery Tests: Percent of Preoperative Baseline Values</span><br><span class="Bold">16 Males, 22 Females, Ages 20-65</span><br><span class="Bold">Percent: Mean Â± SD</span></p></td></tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">60 minutes After Anesthesia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">90 minutes After Anesthesia</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Maintenance:</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Isoflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Isoflurane/N<span class="Sub">2</span>O</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">66 Â± 6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">47 Â± 8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">75 Â± 7<a name="footnote-reference-5" href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">56 Â± 8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">70 Â± 9<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">33 Â± 6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">89 Â± 12<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">47 Â± 8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">66 Â± 5<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">36 Â± 8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">76 Â± 7<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">49 Â± 9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4320789" conceptname="Clumsiness">Clumsiness</span></span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">65 Â± 5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">49 Â± 8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">80 Â± 7<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">57 Â± 9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Comfort</span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">59 Â± 7<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">30 Â± 6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">60 Â± 8<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31 Â± 7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">DSST</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">â€¡</a><span class="Bold"> score</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">74 Â± 4<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">50 Â± 9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">75 Â± 4<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">55 Â± 7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">Trieger Tests</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">Â§</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">67 Â± 5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">74 Â± 6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">90 Â± 6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">83 Â± 7</p></td>
</tr>
</tbody>
</table>
<p>SUPRANE was studied in twelve volunteers receiving no other drugs.  Hemodynamic effects during controlled ventilation (PaCO<span class="Sub">2</span> 38 mm Hg) were:</p>
<table width="100%">
<col width="14%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="10%">
<col width="10%">
<col width="11%">
<col width="11%">
<col width="11%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Differences were statistically significant (p &lt; 0.05) compared to awake values, Newman-Keulâ€™s method of multiple comparison.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="9"><p class="First"><span class="Bold">Hemodynamic Effects of Desflurane During Controlled Ventilation</span><br><span class="Bold">12 Male Volunteers, Ages 16-26</span><br><span class="Bold">Mean Â± SD (Range)</span></p></td></tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">Heart Rate</span><br><span class="Bold">(beats/min)</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First"><span class="Bold">Mean Arterial</span><br><span class="Bold">Pressure </span></p>
<p><span class="Bold">(mm Hg)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac Index</span></span><br><span class="Bold">(L/min/m<span class="Sup">2</span>)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Total MAC Equivalent</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">End-Tidal % Des/O<span class="Sub">2</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">End-Tidal % Des/N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">O<span class="Sub">2</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">O<span class="Sub">2</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N<span class="Sub">2</span>O</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">O<span class="Sub">2</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N<span class="Sub">2</span>O</span></p></td>
</tr>
<tr>
<td class="Lrule" align="center"><p class="First">0</p></td>
<td class="Lrule" align="center"><p class="First">0% / 21%</p></td>
<td class="Lrule" align="center"><p class="First">0% / 0%</p></td>
<td class="Lrule" align="center"><p class="First">69 Â± 4</p></td>
<td class="Lrule" align="center"><p class="First">70 Â± 6</p></td>
<td class="Lrule" align="center"><p class="First">85 Â± 9</p></td>
<td class="Lrule" align="center"><p class="First">85 Â± 9</p></td>
<td class="Lrule" align="center"><p class="First">3.7 Â± 0.4</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3.7 Â± 0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(63 - 76)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(62 - 85)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(74 - 102)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(74 - 102)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(3.0 - 4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(3.0 - 4.2)</p></td>
</tr>
<tr>
<td class="Lrule" align="center"><p class="First">0.8</p></td>
<td class="Lrule" align="center"><p class="First">6% / 94%</p></td>
<td class="Lrule" align="center"><p class="First">3% / 60%</p></td>
<td class="Lrule" align="center"><p class="First">73 Â± 5</p></td>
<td class="Lrule" align="center"><p class="First">77 Â± 8</p></td>
<td class="Lrule" align="center"><p class="First">61 Â± 5<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">69 Â± 5<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">3.2 Â± 0.5</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3.3 Â± 0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(67 - 80)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(67 - 97)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(55 - 70)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(62 - 80)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(2.6 - 4.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(2.6 - 4.1)</p></td>
</tr>
<tr>
<td class="Lrule" align="center"><p class="First">1.2</p></td>
<td class="Lrule" align="center"><p class="First">9% / 91%</p></td>
<td class="Lrule" align="center"><p class="First">6% / 60%</p></td>
<td class="Lrule" align="center"><p class="First">80 Â± 5<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">77 Â± 7</p></td>
<td class="Lrule" align="center"><p class="First">59 Â± 8<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">63 Â± 8<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">3.4 Â± 0.5</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3.1 Â± 0.4<a href="#footnote-8" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(72 - 84)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(67 - 90)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(44 - 71)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(47 - 74)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(2.6 - 4.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(2.6 - 3.8)</p></td>
</tr>
<tr>
<td class="Lrule" align="center"><p class="First">1.7</p></td>
<td class="Lrule" align="center"><p class="First">12% / 88%</p></td>
<td class="Lrule" align="center"><p class="First">9% / 60%</p></td>
<td class="Lrule" align="center"><p class="First">94 Â± 14<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">79 Â± 9</p></td>
<td class="Lrule" align="center"><p class="First">51 Â± 12<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">59 Â± 6<a href="#footnote-8" class="Sup">*</a></p></td>
<td class="Lrule" align="center"><p class="First">3.5 Â± 0.9</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3.0 Â± 0.4<a href="#footnote-8" class="Sup">*</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">(78 - 109)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(61 - 91)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(31 - 66)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(46 - 68)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(1.7 - 4.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(2.4 - 3.6)</p></td>
</tr>
</tbody>
</table>
<p>When the same volunteers breathed spontaneously during desflurane anesthesia, systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and mean arterial <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>; <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>, heart rate, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, and central venous pressure (CVP) increased compared to values when the volunteers were conscious. <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac index</span>, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, and CVP were greater during spontaneous ventilation than during controlled ventilation.</p>
<p>During spontaneous ventilation in the same volunteers, increasing the concentration of SUPRANE from 3% to 12% decreased tidal volume and increased arterial <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> and <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>. The combination of N<span class="Sub">2</span>O 60% with a given concentration of desflurane gave results similar to those with desflurane alone. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> produced by desflurane is similar to that produced by other potent inhalation agents.</p>
<p>The use of desflurane concentrations higher than 1.5 MAC may produce <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<div class="Figure">
<a name="id1636"></a><img alt="Figure 1. PaCO2 During Spontaneous Ventilation in Unstimulated Volunteers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5&amp;name=image-02.jpg"><p class="MultiMediaCaption">Figure 1. PaCO2 During Spontaneous Ventilation in Unstimulated Volunteers</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_b327b4f9-3b7b-4047-921a-c574781f01bc"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Due to the volatile nature of desflurane in plasma samples, the washin-washout profile of desflurane was used as a surrogate of plasma pharmacokinetics. SUPRANE is a volatile liquid inhalation anesthetic minimally biotransformed in the liver in humans. Less than 0.02% of the desflurane absorbed can be recovered as urinary metabolites (compared to 0.2% for isoflurane). Eight healthy male volunteers first breathed 70% N<span class="Sub">2</span>O/30% O<span class="Sub">2</span> for 30 minutes and then a mixture of desflurane 2.0%, isoflurane 0.4%, and halothane 0.2% for another 30 minutes. During this time, inspired and end-tidal concentrations (F<span class="Sub">I</span> and F<span class="Sub">A</span>) were measured. The F<span class="Sub">A</span>/F<span class="Sub">I</span> (washin) value at 30 minutes for desflurane was 0.91, compared to 1.00 for N<span class="Sub">2</span>O, 0.74 for isoflurane, and 0.58 for halothane (see <a href="#_RefIDEAB9634F09104C62A1188E9AED7571F7">Figure 2</a>). The washin rates for halothane and isoflurane were similar to literature values. The washin was faster for desflurane than for isoflurane and halothane at all time points. The F<span class="Sub">A</span>/F<span class="Sub">AO</span> (washout) value at 5 minutes was 0.12 for desflurane, 0.22 for isoflurane, and 0.25 for halothane (see <a href="#_RefID48D9C756B90C4D4183EA95DAA78E1721">Figure 3</a>)<span class="Italics">.</span> The washout for desflurane was more rapid than that for isoflurane and halothane at all elimination time points. By 5 days, the F<span class="Sub">A</span>/F<span class="Sub">AO</span> for desflurane is 1/20th of that for halothane or isoflurane.</p>
<div class="Figure">
<a name="id1936628656"></a><img alt="Figure 2. Desflurane Washin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5&amp;name=image-03.jpg"><p class="MultiMediaCaption">Figure 2. Desflurane Washin</p>
</div>
<div class="Figure">
<a name="id-1928032677"></a><img alt="Figure 3. Desflurane Washout" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5&amp;name=image-04.jpg"><p class="MultiMediaCaption">Figure 3. Desflurane Washout</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_2ecedc8d-652e-4109-af62-486c0ac1a09c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_aba8d9b2-0cc7-49f2-8650-c8771f21f430"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenicity studies have not been performed with desflurane. <span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> genotoxicity studies did not demonstrate mutagenicity or chromosomal damage by desflurane. Tests for genotoxicity included the Ames mutation assay, the metaphase analysis of human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the mouse micronucleus assay.</p>
<p>Fertility was not affected after 1 MAC-Hour per day exposure (cumulative 63 and 14 MAC-Hours for males and females, respectively). At higher doses, parental toxicity (mortalities and reduced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) was observed which could affect fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_072b003a-47cf-4797-bfa8-cf39ab9d8a78"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of SUPRANE was evaluated in 1,843 patients including ambulatory (N=1,061), cardiovascular (N=277), geriatric (N=103), neurosurgical (N=40), and pediatric (N=235) patients. Clinical experience with these patients and with 1,087 control patients in these studies not receiving SUPRANE is described below. Although SUPRANE can be used in adults for the inhalation induction of anesthesia via mask, it produces a high incidence of respiratory irritation (<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, breathholding, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, increased secretions, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>). Oxyhemoglobin saturation below 90% occurred in 6% of patients (from pooled data, NÂ =Â 370 adults).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57a54b40-acc0-47d9-b11c-4aa393c3894f"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Ambulatory Surgery</h2>
<p class="First">SUPRANE plus N<span class="Sub">2</span>O was compared to isoflurane plus N<span class="Sub">2</span>O in multicenter studies (21 sites) of 792 ASA physical status I, II, or III patients aged 18-76 years (median 32).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b5eea55-3bc8-42d3-a41e-056a10030fe9"></a><a name="section-13.1.1"></a><p></p>
<h3><span class="Italics"><span class="Underline">Induction</span></span></h3>
<p class="First">Anesthetic induction begun with thiopental and continued with SUPRANE was associated with a 7% incidence of oxyhemoglobin saturation of 90% or less (from pooled data, N = 307) compared with 5% in patients in whom anesthesia was induced with thiopental and isoflurane (from pooled data, N = 152).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a84ad394-b146-47f1-8322-690949e71b40"></a><a name="section-13.1.2"></a><p></p>
<h3><span class="Italics"><span class="Underline">Maintenance &amp; Recovery</span></span></h3>
<p class="First">SUPRANE (desflurane, USP) with or without N<span class="Sub">2</span>O or other anesthetics was generally well tolerated. There were no differences between SUPRANE and the other anesthetics studied in the times that patients were judged fit for discharge.</p>
<p>In one outpatient study, patients received a standardized anesthetic consisting of thiopental 4.2-4.4 mg/kg, fentanyl 3.5-4.0 Âµg/kg, vecuronium 0.05-0.07 mg/kg, and N<span class="Sub">2</span>O 60% in oxygen with either desflurane 3% or isoflurane 0.6%. Emergence times were significantly different; but times to sit up and discharge were not different (see <a href="#_RefID70BCBBADBA454E51A38DF34573EC87BD">Table 5</a>).</p>
<a name="_RefID70BCBBADBA454E51A38DF34573EC87BD"></a><table width="100%">
<caption><span>Table 5 </span></caption>
<col width="32%">
<col width="26%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Difference was statistically significant from the isoflurane group (p &lt; 0.05), unadjusted for multiple comparisons.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Recovery Profiles After Desflurane 3% in N<span class="Sub">2</span>O 60%</span><br><span class="Bold">vs Isoflurane 0.6% in N<span class="Sub">2</span>O 60% in Outpatients</span><br><span class="Bold">16 Males, 22 Females, Ages 20-65</span><br><span class="Bold">Mean Â± SD</span></p></td></tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Isoflurane</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Desflurane</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Number</p></td>
<td class="Botrule Lrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Anesthetic time (min)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">127 Â± 80</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">     98 Â± 55</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Recovery time to: </p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">  Follow commands (min)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11.1 Â± 7.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">    6.5 Â± 2.3<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">  Sit up (min)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">113 Â± 27</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">     95 Â± 56</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">  Fit for discharge (min)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">231 Â± 40</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">207 Â± 54</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f84d835a-babd-42d9-9e2c-cfa2c4ce0b48"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Cardiovascular Surgery</h2>
<p class="First">SUPRANE was compared to isoflurane, sufentanil or fentanyl for the anesthetic management of coronary artery bypass graft (CABG), <span class="product-label-link" type="condition" conceptid="198177" conceptname="Abdominal aortic aneurysm">abdominal aortic aneurysm</span>, peripheral vascular and carotid endarterectomy surgery in 7 studies at 15 centers involving a total of 558 patients. In all patients except the desflurane vs. sufentanil study, the volatile anesthetics were supplemented with intravenous opioids, usually fentanyl. Blood pressure and heart rate were controlled by changes in concentration of the volatile anesthetics or opioids and cardiovascular drugs if necessary. Oxygen (100%) was the carrier gas in 253 of 277 desflurane cases (24 of 277 received N<span class="Sub">2</span>O/O<span class="Sub">2</span>).</p>
<table width="100%">
<col width="15%">
<col width="16%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="13%">
<col width="13%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="7"><p class="First"><span class="Bold">Cardiovascular Patients by Agent and Type of Surgery</span><br><span class="Bold">418 Males, 140 Females, Ages 27-87 (Median 64)</span></p></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="2">
<p class="First"><span class="Bold">Type of</span></p>
<p><span class="Bold">Surgery </span></p>
</td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">13 Centers</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">1 Center  </span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">1 Center</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Isoflurane</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Sufentanil</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Desflurane</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Fentanyl</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Desflurane</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">CABG</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">58</p></td>
<td class="Botrule Lrule" align="center"><p class="First">57</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Abd Aorta</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Periph Vasc</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Carotid Art</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">45</p></td>
<td class="Botrule Lrule" align="center"><p class="First">46</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">Total</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">156</p></td>
<td class="Botrule Lrule" align="center"><p class="First">152</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25</p></td>
</tr>
</tbody>
</table>
<p>No differences were found in cardiovascular outcome (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>) among desflurane and the other anesthetics.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bf41e0f-111f-45f9-bfb2-5a35870cdca9"></a><a name="section-13.2.1"></a><p></p>
<h3><span class="Italics"><span class="Underline">Induction</span></span></h3>
<p class="First">SUPRANE should not be used as the sole agent for anesthetic induction in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or any patients where increases in heart rate or blood pressure are undesirable. In the desflurane vs. sufentanil study, anesthetic induction with desflurane without opioids was associated with new transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> in 14 patients vs. 0 in the sufentanil group. In the desflurane group, mean heart rate, arterial pressure, and pulmonary <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span> and <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> decreased in contrast to no change in the sufentanil group. Cardiovascular drugs were used frequently in both groups: especially esmolol in the desflurane group (56% vs. 0%) and phenylephrine in the sufentanil group (43% vs. 27%). When 10 Âµg/kg of fentanyl was used to supplement induction of anesthesia at one other center, continuous 2-lead ECG analysis showed a low incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and no difference between desflurane and isoflurane. If desflurane is to be used in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, it should be used in combination with other medications for induction of anesthesia, preferably intravenous opioids and hypnotics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61edcf9e-7eea-49fb-96a1-0251958b2240"></a><a name="section-13.2.2"></a><p></p>
<h3><span class="Italics"><span class="Underline">Maintenance &amp; Recovery</span></span></h3>
<p class="First">In studies where SUPRANE or isoflurane anesthesia was supplemented with fentanyl, there were no differences in hemodynamic variables or the incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in the patients anesthetized with desflurane compared to those anesthetized with isoflurane.</p>
<p>During the precardiopulmonary bypass period, in the desflurane vs. sufentanil study where the desflurane patients received no intravenous opioid, more desflurane patients required cardiovascular adjuvants to control hemodynamics than the sufentanil patients. During this period, the incidence of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> detected by ECG or echocardiography was not statistically different between desflurane (18 of 99) and sufentanil (9 of 98) groups. However, the duration and severity of ECG-detected <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> was significantly less in the desflurane group. The incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> after cardiopulmonary bypass and in the ICU did not differ between groups. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eeb61e04-a960-4e52-bf8f-89268d30b3d6"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Geriatric Surgery</h2>
<p class="First">SUPRANE plus N<span class="Sub">2</span>O was compared to isoflurane plus N<span class="Sub">2</span>O in a multicenter study (6 sites) of 203 ASA physical status II or III elderly patients, aged 57-91 years (median 71).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93289444-2869-4222-bb55-490b2e699862"></a><a name="section-13.3.1"></a><p></p>
<h3><span class="Italics"><span class="Underline">Induction</span></span></h3>
<p class="First">Most patients were premedicated with fentanyl (mean 2 Âµg/kg), preoxygenated, and received thiopental (mean 4.3 mg/kg IV) or thiamylal (mean 4 mg/kg IV) followed by succinylcholine (mean 1.4 mg/kg IV) for intubation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39f63da0-4968-4337-9715-c7fcc6cf0b54"></a><a name="section-13.3.2"></a><p></p>
<h3><span class="Italics"><span class="Underline">Maintenance &amp; Recovery</span></span></h3>
<p class="First">Heart rate and arterial blood pressure remained within 20% of preinduction baseline values during administration of SUPRANE 0.5-7.7% (average 3.6%) with 50-60% N<span class="Sub">2</span>O. Induction, maintenance, and recovery cardiovascular measurements did not differ from those during isoflurane/N<span class="Sub">2</span>O administration nor did the postoperative incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> differ. The most common cardiovascular adverse event was <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurring in 8% of the desflurane patients and 6% of the isoflurane patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6335d1c-45fc-49f8-805f-83432d845bfb"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Neurosurgery</h2>
<p class="First">SUPRANE was studied in 38 patients aged 26-76 years (median 48Â years), ASA physical status II or III undergoing neurosurgical procedures for intracranial lesions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04ed342f-9196-47b2-bba9-6c044a002433"></a><a name="section-13.4.1"></a><p></p>
<h3><span class="Italics"><span class="Underline">Induction</span></span></h3>
<p class="First">Induction consisted of standard neuroanesthetic techniques including <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and thiopental.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9514df0d-6f8b-4913-8820-ebdf8251e046"></a><a name="section-13.4.2"></a><p></p>
<h3><span class="Italics"><span class="Underline">Maintenance</span></span></h3>
<p class="First">No change in cerebrospinal fluid pressure (CSFP) was observed in 8 patients who had intracranial tumors when the dose of SUPRANE was 0.5 MAC in N<span class="Sub">2</span>O 50%. In another study of 9 patients with intracranial tumors, 0.8 MAC desflurane/air/O<span class="Sub">2</span> did not increase CSFP above post induction baseline values. In a different study of 10 patients receiving 1.1 MAC desflurane/air/O<span class="Sub">2</span>, CSFP increased 7 mm Hg (range 3-13 mm Hg increase, with final values of 11-26 mm Hg) above the pre-drug values.</p>
<p>All volatile anesthetics may increase intracranial pressure in patients with intracranial space occupying lesions. In such patients, SUPRANE should be administered at 0.8 MAC or less, and in conjunction with a barbiturate induction and <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> (hypocapnia) in the period before cranial decompression. Appropriate attention must be paid to maintain cerebral perfusion pressure. The use of a lower dose of SUPRANE (desflurane, USP) and the administration of a barbiturate and mannitol would be predicted to lessen the effect of desflurane on CSFP.</p>
<p>Under hypocapnic conditions (PaCO<span class="Sub">2</span> 27 mm Hg) SUPRANE 1 and 1.5 MAC did not increase cerebral blood flow (CBF) in 9 patients undergoing craniotomies. CBF reactivity to increasing PaCO<span class="Sub">2</span> from 27 to 35 mm Hg was also maintained at 1.25 MAC desflurane/air/O<span class="Sub">2</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_baf2684e-9712-496a-8729-ea85bf551de3"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Pediatric Surgery</h2>
<p class="First">In a clinical safety trial conducted in children aged 2 to 16 years (mean 7.4 years), following induction with another agent, SUPRANE and isoflurane (in N<span class="Sub">2</span>O/O<span class="Sub">2</span>) were compared when delivered via face mask or laryngeal mask airway (LMAâ„¢ mask) for maintenance of anesthesia, after induction with intravenous propofol or inhaled sevoflurane, in order to assess the relative incidence of respiratory adverse events.</p>
<table width="100%">
<col width="20%">
<col width="23%">
<col width="18%">
<col width="19%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Minor, moderate and severe respiratory events</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Maintenance in Nonintubated Pediatric Patients</span><br><span class="Bold">(Face Mask or LMAâ„¢ mask Used; N=300)</span><br><span class="Bold">All Respiratory Events</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a><span class="Bold"> (&gt;1% of All Pediatric Patients)</span></p></td></tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">All Ages</span><br><span class="Bold">(N=300)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">2-6 yr</span><br><span class="Bold">(N=150)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">7-11 yr</span><br><span class="Bold">(N=81)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">12-16 yr</span><br><span class="Bold">(N=69)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Any  respiratory events</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">39%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">42%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">33%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">39%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Airway obstruction</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Breath-holding</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span> </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">26%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">33%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">19%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">Laryngospasm</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">13%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Secretion</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">12%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Non-specific desaturation</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
</tbody>
</table>
<p>SUPRANE was associated with higher rates (compared with isoflurane) of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions with an overall rate of respiratory events of 39%. Of the pediatric patients exposed to desflurane, 5% experienced severe <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> (associated with significant desaturation; <span class="Italics">i.e.</span> SpO2 of &lt;90% for &gt;15 seconds, or requiring succinylcholine), across all ages, 2-16 years old. Individual age group incidences of severe <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> were 9% for 2-6 years old, 1% for 7-11 years old, and 1% for 12-16 years old. Removal of LMAâ„¢ mask under deep anesthesia (MAC range 0.6 â€“ 2.3 with a mean of 1.12 MAC) was associated with a further increase in frequency of respiratory adverse events as compared to awake LMAâ„¢ mask removal or LMAâ„¢ mask removal under deep anesthesia with the comparator. The frequency and severity of non-respiratory adverse events were comparable between the two groups.</p>
<p>The incidence of respiratory events under these conditions was highest in children aged 2-6 years. Therefore, similar studies in children under the age of 2 years were not initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_466eb430-3e2e-493e-b58c-7e492bafe4a4"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">SUPRANE (desflurane, USP) is available in an amber-colored glass bottle or an aluminum bottle containing 240 mL of desflurane as follows:</p>
<table width="100%">
<col width="26%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">NDC</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Container</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Unit(s)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">10019-646-60</p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First">Amber-colored Glass</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">10019-646-24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">10019-646-64</p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First">Aluminum Bottle</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">10019-646-34</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f2c5548-9bb8-4676-902d-5b33af853472"></a><a name="section-14.1"></a><p></p>
<h2>16.1 Safety and Handling</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3f69bd2-cf3b-44a1-90d4-54102825ef91"></a><a name="section-14.1.1"></a><p></p>
<h3><span class="Italics"><span class="Underline">Occupational Caution</span></span></h3>
<p class="First">There is no specific work exposure limit established for SUPRANE. However, the National Institute for Occupational Safety and Health Administration (NIOSH) recommends that no worker should be exposed at ceiling concentrations greater than 2 ppm of any halogenated anesthetic agent over a sampling period not to exceed one hour.</p>
<p>Principle routes of exposure include:</p>
<p>Skin contact â€“ May cause <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>. In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Seek medical attention if irritation develops.</p>
<p>Eye contact â€“ May cause <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>. In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Seek medical attention if irritation develops.</p>
<p>Ingestion â€“ No specific hazards other than therapeutic effects. Do NOT induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> unless directed to do so by medical personnel. Never give anything by mouth to an <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> person. If large quantities of this material are swallowed, seek medical attention immediately.</p>
<p>Inhalation â€“ If individuals smell vapors, or experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, they should be moved to an area with fresh air. Individuals could also experience the following: Cardiovascular effects: may include fluctuations in heart rate, changes in blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. Respiratory effects: may include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasms</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Gastrointestinal effects: may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, loss of appetite. Nervous System effects: may include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, disturbance of speech, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p>The predicted effects of acute overexposure by inhalation of SUPRANE include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or (in extreme cases) <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> [see <a href="#i4i_overdosage_id_8655c2da-7c96-430a-9c86-e0e3cbd58327">Overdosage (10)</a>].</p>
<p>There are no documented adverse effects of chronic exposure to halogenated anesthetic vapors (<span class="Underline">W</span>aste <span class="Underline">A</span>nesthetic <span class="Underline">G</span>ases or WAGs) in the workplace. Although results of some epidemiological studies suggest a link between exposure to halogenated anesthetics and increased health problems (particularly <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>), the relationship is not conclusive. Since exposure to WAGs is one possible factor in the findings for these studies, operating room personnel, and pregnant women in particular, should minimize exposure.  Precautions include adequate general ventilation in the operating room, the use of a well-designed and well-maintained scavenging system; work practices to minimize leaks and spills while the anesthetic agent is in use, and routine equipment maintenance to minimize leaks.</p>
<p>Consistent with clinical data, concentrations would need to reach 2-3% in inspired air before individuals would likely experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or other physiologic effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a19508a3-3833-4474-b452-361c0be0467e"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at room temperature, 15Â°-30Â°C (59Â°-86Â°F).  SUPRANE (desflurane, USP) has been demonstrated to be stable for the period defined by the expiration dating on the label. The bottle should be recapped after each use of SUPRANE (desflurane, USP).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_e8f24397-eff7-46fa-88fe-49762593982d"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Anesthesia providers need to obtain the following information from patients prior to administration of anesthesia:</p>
<dl>
<dt>â€¢</dt>
<dd>Medications they are taking, including herbal supplements</dd>
<dt>â€¢</dt>
<dd>Drug allergies, including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to anesthetic agents (including hepatic sensitivity)</dd>
<dt>â€¢</dt>
<dd>Any history of severe reactions to prior administration of anesthetic</dd>
<dt>â€¢</dt>
<dd>If the patient or a member of the patientâ€™s family has a history of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> or if the patient has a history of <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span> or other latent neuromuscular disease</dd>
</dl>
<p>Anesthesia providers should inform patients of the risks associated with SUPRANE:</p>
<dl>
<dt>â€¢</dt>
<dd>Post-operative <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and respiratory adverse effects including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>.</dd>
<dt>â€¢</dt>
<dd>There is no information of the effects of SUPRANE following anesthesia on the ability to operate an automobile or other heavy machinery. However, patients should be advised that the ability to perform such tasks may be impaired after receiving anesthetic agents.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_896f9f4d-de0c-4c38-9302-fb2ccce6ccdd"></a><a name="section-16"></a><p></p>
<p class="First">************************************************************************</p>
<p>Baxter and Suprane are registered trademarks of Baxter International Inc.</p>
<p>Amerinet Choice is a registered trademark of Amerinet, Inc.</p>
<p>Please insert Amerinet logo. </p>
<p>Manufactured for</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Deerfield, IL 60015 USA </p>
<p>and Amerinet Choice</p>
<p>2060 Craigshire Road</p>
<p>St. Louis, MO 63146</p>
<p>************************************************************************</p>
<p>Revised 02/2015</p>
<p>	               07-19-74-619</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_9f9c66c9-d7b0-49a3-b2c0-03f330f215b8"></a><a name="section-17"></a><p></p>
<h1>PACKAGING LABELING - PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id2061"></a><img alt="Suprane Amerinet Choice Representative Container Label  NDC 10019-646-24" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5&amp;name=image-05.jpg"><p class="MultiMediaCaption">Container Label</p>
</div>
<p class="First">NDC 10019-646-24</p>
<p><span class="Bold">Suprane</span></p>
<p>(desflurane, USP)<br><span class="Bold">Liquid for Inhalation</span><br>240 mL</p>
<p><span class="Bold">Rx</span> only</p>
<p><span class="Bold">Amerinet Choice logo</span></p>
<p>Manufactured for<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015<br>and Amerinet Choice<br>2060 Craigshire Road<br>St. Louis, MO 63146</p>
<p>(Â±) 1,2,2,2 - tetrafluoroethyl<br>difluoromethyl ether<br>A nonflammable, nonexplosive<br>inhalation anesthetic</p>
<p><span class="Bold">Store at room temperature 15Â°-30Â°C</span><br><span class="Bold">(59Â°-86Â°F).</span></p>
<p>Replace cap after each use.</p>
<p><span class="Bold">IMPORTANT: </span>See package insert for<br>dosage and directions for use.<br>For Product Inquiry 1 800 ANA DRUG<br>(1-800-262-3784)</p>
<p>460-664-01</p>
<p>N 3 10019 64624 4</p>
<div class="Figure">
<a name="id2098"></a><img alt="Suprane Amerinet Choice Representative Carton Label  NDC 10019-646-34" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5&amp;name=image-06.jpg"><p class="MultiMediaCaption">Carton Label</p>
</div>
<p><span class="Bold">SUPRANE</span>                NDC 10019-646-34<br>(desflurane, USP)      6 x 240 mL Bottles</p>
<p>Store at room temperature 15Â°-30Â°C (59Â°-86Â°F).</p>
<p>Exp 99 8888        Lot XXXXXXXXXX</p>
<p>(17) 889900 (10) XXXXXXXXXX </p>
<p>(01) 5 0310019 64634 8(30) 0006</p>
<p>Mfd. for Baxter Healthcare Corporation, Deerfield, IL 60015<br>and Amerinet Choice, St. Louis, MO 63146</p>
<p>0000    07-06-71-116</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUPRANEÂ 		
					</strong><br><span class="contentTableReg">desflurane liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-646</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DESFLURANE</strong> (DESFLURANE) </td>
<td class="formItem">DESFLURANE</td>
<td class="formItem">240Â mL Â inÂ 240Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-646-24</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem">09/18/1992</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-646-60</td>
<td class="formItem">240 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:10019-646-34</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem">09/18/1992</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:10019-646-64</td>
<td class="formItem">240 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020118</td>
<td class="formItem">09/18/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare of Puerto Rico</td>
<td class="formItem"></td>
<td class="formItem">154731033</td>
<td class="formItem">ANALYSIS(10019-646), LABEL(10019-646), MANUFACTURE(10019-646), PACK(10019-646), API MANUFACTURE(10019-646)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c1b09e56-d609-412c-b5b5-c0ec305e56e8</div>
<div>Set id: 7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5</div>
<div>Version: 5</div>
<div>Effective Time: 20150226</div>
</div>
</div>Â <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
